(Q39822907)

14 September 2017

Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma (English)

1 reference

14 September 2017

0 references

T Tajiri

1

1 reference

14 September 2017

H Matsumoto

2

1 reference

14 September 2017

Y Gon

3

1 reference

14 September 2017

R Ito

4

1 reference

14 September 2017

S Hashimoto

5

1 reference

14 September 2017

K Izuhara

6

1 reference

14 September 2017

M Suzukawa

7

1 reference

14 September 2017

K Ohta

8

1 reference

14 September 2017

J Ono

9

1 reference

14 September 2017

S Ohta

10

1 reference

14 September 2017

I Ito

11

1 reference

14 September 2017

T Oguma

12

1 reference

14 September 2017

H Inoue

13

1 reference

14 September 2017

T Iwata

14

1 reference

14 September 2017

Y Kanemitsu

15

1 reference

14 September 2017

T Nagasaki

16

1 reference

14 September 2017

A Niimi

17

1 reference

14 September 2017

M Mishima

18

1 reference

14 September 2017

26 April 2016

1 reference

14 September 2017

1 reference

14 September 2017

71

1 reference

14 September 2017

10

1 reference

14 September 2017

1472-1479

1 reference

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

14 September 2017

1 reference

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

21 January 2018

1 reference

Omalizumab in asthma: an update on recent developments

21 January 2018

1 reference

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

Omalizumab-induced reductions in mast cell Fce psilon RI expression and function

21 January 2018

1 reference

Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.

21 January 2018

1 reference

Monitoring free serum IgE in severe asthma patients treated with omalizumab.

21 January 2018

1 reference

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

21 January 2018

1 reference

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study

21 January 2018

1 reference

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

21 January 2018

1 reference

Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study.

21 January 2018

1 reference

Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids

21 January 2018

1 reference

Prevalence and clinical relevance of allergic rhinitis in patients with classic asthma and cough variant asthma

21 January 2018

1 reference

ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005.

21 January 2018

1 reference

Development of assay for determining free IgE levels in serum from patients treated with omalizumab.

21 January 2018

1 reference

Recent asthma exacerbations: a key predictor of future exacerbations

21 January 2018

1 reference

High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects.

21 January 2018

1 reference

Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals.

21 January 2018

1 reference

Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients

21 January 2018

1 reference

Integrating longitudinal information on pulmonary function and inflammation using asthma phenotypes.

21 January 2018

1 reference

Serum periostin: a novel biomarker for asthma management

21 January 2018

1 reference

The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma.

21 January 2018

1 reference

Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.

21 January 2018

1 reference

Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation

21 January 2018

1 reference

"Auto-anti-IgE": naturally occurring IgG anti-IgE antibodies may inhibit allergen-induced basophil activation.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/ALL.12922

1 reference

14 September 2017

1 reference